Exelixis and Merck Establish Chemistry Collaboration

Companies Combine Chemistry Expertise to Create Novel Libraries

02-May-2002 - SOUTH SAN FRANCISCO, Calif. May 1, 2002 Exelixis, Inc. has established a collaboration with Merck & Co., Inc. for the joint design and generation of small molecule compound libraries for high throughput drug screening. These custom libraries will be owned by both companies and will be designed ...

Tripos to Build One of the Leading Informatics-Driven Drug Discovery Laboratories in Europe

- State-of-the-Art Chemical Synthesis Facilities to be Built in Cornwall, England -

29-Apr-2002 - ST. LOUIS, MO - April 25, 2002 - Responding to worldwide demand by pharmaceutical and biotechnology companies to accelerate timelines in the discovery of new drugs and therapeutics for the marketplace, the leading provider of drug discovery chemistry, software and enterprise informatics, Tripos, ...

Bruker AXS Acquires MAC Science to Further Penetrate Japanese Life Science and Materials Research Markets

19-Apr-2002 - Bruker AXS Inc, a leading global provider of advanced X-ray solutions for the life and advanced materials sciences, today announced that its wholly owned Japanese subsidiary, Nihon Bruker AXS K.K., has signed a binding agreement to acquire substantially all the assets and certain liabilities of ...

Agilent Technologies to enhance proteomics solutions with addition of AP-MALDI from MassTech Inc.

11-Apr-2002 - PALO ALTO, Calif., Agilent Technologies Inc. announced an agreement with MassTech Inc. of Burtonsville, Maryland. Under the terms of the agreementAgilent and MassTech are expected to develop a customized version of MassTech's atmospheric pressure matrix-assisted laser desorption/ionization ...

SciQuest Launches Research Newsfeed and Private Portal Solutions Derived From Its SciCentral News Portal

Technology and content aggregation from award-winning portal will be licensed and syndicated

20-Feb-2002 - RESEARCH TRIANGLE PARK, N.C., Feb 19, 2002 (BW HealthWire) --SciQuest, Inc., a software, information and services company that provides solutions to enhance research operations for pharmaceutical, biotechnology and other research-based organizations, announced today two new products derived from ...

Celera Compound Enters Development for Chagas' Disease

19-Feb-2002 - Rockville, MD and San Francisco, CA—February 14, 2002--Celera Genomics, an Applera Corporation business, announced today that the Institute for OneWorld Health (IOWH) and the National Institutes of Health (NIH) have initiated development of CRA-3316 as a potential new treatment for Chagas' ...

New Sigma Catalog is "The Source" for Life Science Research

08-Jan-2002 - ST. LOUIS, Jan 7, 2002 -- Sigma-Aldrich has just released its Sigma division's latest catalog of Biochemicals and Reagents for Life Science Research. With over 5,000 new products and an easier-to-use format, the catalog, along with Sigma's strong tradition of excellent service and unrivaled ...

Tripos Announces Partnership With Pfizer

Software License Covers Worldwide Access to Tripos' Discovery Technologies

04-Jan-2002 - ST. LOUIS, MO - January 3, 2002 - Tripos, Inc. a provider of drug discovery chemistry, software and services, today announced a multi-million dollar, multi-year agreement with Pfizer Global Research and Development to license its suite of discovery software technologies, including the ...

Tripos Announces its Latest Release of its Software for Drug Discovery

20-Dec-2001 - St. Louis, MO - December 18, 2001 -- Tripos, Inc., a leading provider of drug discovery chemistry, software and services, today announced the release of the latest version of its industry-leading computational platform for drug design and discovery, SYBYL®6.8/UNITY®4.3. The new software release ...

Albany Molecular Research, Inc. Partners with National Cancer Institute to Develop Anti-Cancer Drugs

14-Dec-2001 - Albany, NY (December 13, 2001) - Albany Molecular Research, Inc. announced the signing of a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute to develop anti-cancer compounds. Under the terms of the five-year agreement, scientists from both AMRI and the ...